HSP90通过维持强直性B细胞受体信号促进伯基特淋巴瘤细胞存活
研究在17个伯基特淋巴瘤(BL)细胞系中进行化合物筛选,发现热休克蛋白90(HSP90)抑制剂在体外以不影响正常B细胞的浓度诱导BL细胞凋亡。蛋白质组与磷酸化蛋白质组分析显示HSP90抑制削弱脾酪氨酸激酶(SYK)活性,SYK被鉴定为HSP90客户蛋白;表达组成性活跃的TEL-SYK可抵消HSP90抑制剂的凋亡效应。结果提示HSP90抑制剂通过干扰强直性BCR信号损害BL细胞存活,为HSP90抑制剂治疗BL提供分子依据。
要点
- HSP90抑制剂在体外以不影响正常B细胞的浓度诱导BL细胞凋亡。
- SYK被鉴定为HSP90客户蛋白,HSP90抑制削弱SYK活性。
- 组成性活跃TEL-SYK表达可抵消HSP90抑制剂的凋亡效应。
核心结论
- HSP90抑制通过干扰强直性BCR信号损害BL细胞存活,为HSP90抑制剂用于BL治疗提供分子依据。
研究设计与样本
- 在17个BL细胞系中进行化合物筛选以识别影响细胞存活的小分子抑制剂,并进行全球蛋白质组与磷酸化蛋白质组分析。
主要发现
- HSP90抑制剂在体外以不影响正常B细胞的浓度诱导BL细胞凋亡。
- HSP90抑制削弱BL中 pivotal BCR近端效应器SYK的活性,SYK被鉴定为HSP90客户蛋白。
- 表达组成性活跃的TEL-SYK可抵消HSP90抑制的凋亡效应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Burkitt lymphoma (BL) is an aggressive B-cell neoplasm that is currently treated by intensive chemotherapy in combination with anti-CD20 antibodies. Because of their toxicity, current treatment regimens are often not suitable for elderly patients or for patients in developing countries where BL is endemic. Targeted therapies for BL are therefore needed. In this study, we performed a compound screen in 17 BL cell lines to identify small molecule inhibitors affecting cell survival. We found that inhibitors of heat shock protein 90 (HSP90) induced apoptosis in BL cells in vitro at concentrations that did not affect normal B cells. By global proteomic and phosphoproteomic profiling, we show that, in BL, HSP90 inhibition compromises the activity of the pivotal B-cell antigen receptor (BCR)-proximal effector spleen tyrosine kinase (SYK), which we identified as an HSP90 client protein. Consistently, expression of constitutively active TEL-SYK counteracted the apoptotic effect of HSP90 inhibition. Together, our results demonstrate that HSP90 inhibition impairs BL cell survival by interfering with tonic BCR signaling, thus providing a molecular rationale for the use of HSP90 inhibitors in the treatment of BL.
引用
- Walter R, Pan KT, Doebele C, et al. HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. Blood. 2016. PMID: 28064214. doi:10.1182/blood-2016-06-721423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。